ANIKA THERAPEUTICS INC (ANIK) Stock Fundamental Analysis

NASDAQ:ANIK • US0352551081

10.06 USD
-0.19 (-1.85%)
At close: Feb 12, 2026
10.06 USD
0 (0%)
After Hours: 2/12/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall ANIK gets a fundamental rating of 4 out of 10. We evaluated ANIK against 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ANIK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ANIK has reported negative net income.
  • In the past year ANIK had a positive cash flow from operations.
  • ANIK had negative earnings in 4 of the past 5 years.
  • Of the past 5 years ANIK 4 years had a positive operating cash flow.
ANIK Yearly Net Income VS EBIT VS OCF VS FCFANIK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

  • With a decent Return On Assets value of -32.30%, ANIK is doing good in the industry, outperforming 64.44% of the companies in the same industry.
  • The Return On Equity of ANIK (-41.05%) is better than 70.36% of its industry peers.
Industry RankSector Rank
ROA -32.3%
ROE -41.05%
ROIC N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ANIK Yearly ROA, ROE, ROICANIK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

  • ANIK's Gross Margin of 56.82% is fine compared to the rest of the industry. ANIK outperforms 77.63% of its industry peers.
  • In the last couple of years the Gross Margin of ANIK has declined.
  • The Profit Margin and Operating Margin are not available for ANIK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
ANIK Yearly Profit, Operating, Gross MarginsANIK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ANIK has been reduced compared to 1 year ago.
  • ANIK has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANIK Yearly Shares OutstandingANIK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANIK Yearly Total Debt VS Total AssetsANIK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 3.64 indicates that ANIK is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ANIK (3.64) is better than 70.17% of its industry peers.
  • ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.64
ROIC/WACCN/A
WACC12.4%
ANIK Yearly LT Debt VS Equity VS FCFANIK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 6.18 indicates that ANIK has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.18, ANIK is in the better half of the industry, outperforming 62.91% of the companies in the same industry.
  • ANIK has a Quick Ratio of 5.12. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
  • ANIK has a Quick ratio of 5.12. This is comparable to the rest of the industry: ANIK outperforms 58.32% of its industry peers.
Industry RankSector Rank
Current Ratio 6.18
Quick Ratio 5.12
ANIK Yearly Current Assets VS Current LiabilitesANIK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.18% over the past year.
  • The Revenue for ANIK has decreased by -31.29% in the past year. This is quite bad
  • Measured over the past years, ANIK shows a small growth in Revenue. The Revenue has been growing by 0.91% on average per year.
EPS 1Y (TTM)53.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)-31.29%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-28.22%

3.2 Future

  • The Earnings Per Share is expected to grow by 28.24% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ANIK will show a quite strong growth in Revenue. The Revenue will grow by 11.88% on average per year.
EPS Next Y46.29%
EPS Next 2Y25.65%
EPS Next 3Y22.37%
EPS Next 5Y28.24%
Revenue Next Year-26.08%
Revenue Next 2Y-11.98%
Revenue Next 3Y-6.74%
Revenue Next 5Y11.88%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ANIK Yearly Revenue VS EstimatesANIK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
ANIK Yearly EPS VS EstimatesANIK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANIK. In the last year negative earnings were reported.
  • Also next year ANIK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIK Price Earnings VS Forward Price EarningsANIK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANIK Per share dataANIK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ANIK's earnings are expected to grow with 22.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.65%
EPS Next 3Y22.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ANIK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANIKA THERAPEUTICS INC

NASDAQ:ANIK (2/12/2026, 8:00:00 PM)

After market: 10.06 0 (0%)

10.06

-0.19 (-1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-10
Inst Owners85.74%
Inst Owner Change0.65%
Ins Owners4.2%
Ins Owner Change0%
Market Cap145.07M
Revenue(TTM)112.81M
Net Income(TTM)-60.63M
Analysts85
Price Target16.32 (62.23%)
Short Float %5.21%
Short Ratio4.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-70.46%
Min EPS beat(2)-132.56%
Max EPS beat(2)-8.36%
EPS beat(4)0
Avg EPS beat(4)-518.35%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-8.36%
EPS beat(8)0
Avg EPS beat(8)-472.04%
EPS beat(12)2
Avg EPS beat(12)-316.38%
EPS beat(16)5
Avg EPS beat(16)-229.59%
Revenue beat(2)1
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-8.59%
Max Revenue beat(2)2.34%
Revenue beat(4)2
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)3.46%
Revenue beat(8)5
Avg Revenue beat(8)-0.68%
Revenue beat(12)8
Avg Revenue beat(12)0.79%
Revenue beat(16)12
Avg Revenue beat(16)2.36%
PT rev (1m)0%
PT rev (3m)3.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)14.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF 23.1
P/B 0.98
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-2.28
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.44
OCFY4.33%
SpS8.58
BVpS10.24
TBVpS9.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.3%
ROE -41.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.82%
FCFM N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
F-Score6
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 105.79%
Cap/Sales 5.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.18
Quick Ratio 5.12
Altman-Z 3.64
F-Score6
WACC12.4%
ROIC/WACCN/A
Cap/Depr(3y)64.17%
Cap/Depr(5y)48.11%
Cap/Sales(3y)5.41%
Cap/Sales(5y)4.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y46.29%
EPS Next 2Y25.65%
EPS Next 3Y22.37%
EPS Next 5Y28.24%
Revenue 1Y (TTM)-31.29%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-28.22%
Revenue Next Year-26.08%
Revenue Next 2Y-11.98%
Revenue Next 3Y-6.74%
Revenue Next 5Y11.88%
EBIT growth 1Y9.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.73%
EBIT Next 3Y32.37%
EBIT Next 5Y36.1%
FCF growth 1Y92.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y172.01%
OCF growth 3Y-13.68%
OCF growth 5Y-31.94%

ANIKA THERAPEUTICS INC / ANIK FAQ

What is the fundamental rating for ANIK stock?

ChartMill assigns a fundamental rating of 4 / 10 to ANIK.


What is the valuation status of ANIKA THERAPEUTICS INC (ANIK) stock?

ChartMill assigns a valuation rating of 1 / 10 to ANIKA THERAPEUTICS INC (ANIK). This can be considered as Overvalued.


Can you provide the profitability details for ANIKA THERAPEUTICS INC?

ANIKA THERAPEUTICS INC (ANIK) has a profitability rating of 2 / 10.


Can you provide the financial health for ANIK stock?

The financial health rating of ANIKA THERAPEUTICS INC (ANIK) is 8 / 10.


Can you provide the expected EPS growth for ANIK stock?

The Earnings per Share (EPS) of ANIKA THERAPEUTICS INC (ANIK) is expected to grow by 46.29% in the next year.